ジスキネジア市場：治療タイプ別、ジスキネジアタイプ別、投与経路別、原因別、患者ケア環境別-2025～2030年の世界予測

ジスキネジア市場は、2024年には24億2,000万米ドルとなり、2025年には25億9,000万米ドル、CAGR 7.30%で成長し、2030年には37億米ドルに達すると予測されています。

進化する医療において、ジスキネジアは依然として重要な研究セグメントであり、注目されています。本レポートでは、ジスキネジア市場を詳細に調査し、その現状と将来の可能性を明らかにします。まず、患者のQOLに影響を及ぼす不随意筋運動を特徴とする運動障害であるジスキネジアの臨床的性質について重点的に分析します。医療専門家や意思決定者がこの疾患によってもたらされる課題に対処するために、本レポートは実証的調査と戦略的市場分析を組み合わせて掘り下げています。本レポートでは、歴史的動向、診断の複雑さ、包括的な治療オプションに対する差し迫ったニーズについて考察しています。明確かつ直接的な分析を通じて、本レポートは多面的な市場力学と様々な利害関係者の役割を理解するための基礎を築きます。膨大な臨床データと新たな治療パラダイムから導き出された豊富な洞察は、タイムリーな医療介入と全人的な患者ケアの重要性を強調しています。この採用では、その後の各章を構成する背景を明らかにし、読者に市場の変容と細分化された洞察の探求を促し、市場の進化について十分な情報を記載しています。

ジスキネジア市場の変革

近年、ジスキネジア市場は、技術と医療研究の急速な進歩に牽引され、変貌を遂げてきました。革新的な治療プロトコルと診断技術の向上が統合され、より個別化された効果的な治療戦略が可能になったことで、その様相は一変しました。包括的なデータ分析と並ぶ臨床上のブレークスルーは、精密医療が治療レジメンの中心となる段階へと市場を押し上げました。従来の方法論は、症状に対処するだけでなく、ジスキネジアの根本的な原因やニュアンスも対象とする、エビデンスによる患者中心のアプローチに取って代わられつつあります。この新たなパラダイムにおいて、利害関係者はデジタルソリューション、遠隔医療、強化されたモニタリングシステムを取り入れており、これらは共に、より機敏で適応性の高い治療フレームワークに貢献しています。進化する規制基準や独創的な臨床検査デザインにより、新たな治療法に関する実臨床でのエビデンスを収集することが重視されるようになっています。このような継続的な変革は、ジスキネジアに対する理解を深めるだけでなく、新規治療法の開発を刺激し、市場がダイナミックであり続け、患者の複雑なニーズに対応できることを保証しています。

詳細な市場セグメンテーションによる市場展望

市場は広範なセグメンテーションにより細分化され、治療戦略や患者との相互作用に関する詳細な洞察が得られます。治療タイプを考慮する場合、市場は非薬理学的アプローチ、薬理学的治療、外科的介入にわたって調査されます。非薬理学的カテゴリーは、行動療法や理学療法、リハビリテーションプロトコルを調査することでさらに細かく分類され、薬理学的治療は抗コリン薬、ドーパミンモジュレーター、GABAアゴニスト、NMDA受容体アンタゴニスト、VMAT2阻害剤などのグループに細かく分類されています。外科的治療は、切除手術とますます重要性を増している脳深部刺激療法の両方を評価することによって分析されます。さらに、ジスキネジアのタイプによるセグメンテーションにより、アテトーゼ、コレア、ジストニア関連ジスキネジア、ミオクロニー性ジスキネジア、パーキンソン病ジスキネジア、痙攣性斜頸、遅発性ジスキネジアなどの病態を分類することができます。投与経路は、静脈内投与、点滴投与、経口投与、皮下投与、経皮投与などを区別することで、さらに先進的ものとなります。さらに、薬剤誘発性、遺伝性、特発性、代謝性ジスキネジアから神経変性障害に伴うジスキネジアまで、根本的な原因を理解することが包括的な枠組みを記載しています。最後に、市場は患者のケア環境に基づいてさらに細分化され、在宅ケア、病院、研究機関、専門クリニック、リハビリテーションセンターなどが含まれます。このような多角的なセグメンテーションにより、ジスキネジア患者の多様なニーズに対応するために必要な複雑性と個別化されたアプローチが浮き彫りにされます。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • パーキンソン病やその他の神経疾患の有病率の増加
    • 支援的な規制施策と迅速な医薬品承認プロセスがジスキネジア治療の市場成長を促進
    • 医療従事者と患者の間でジスキネジアとその管理に関する意識を高める
  • 抑制要因
    • ジスキネジア管理のための治療と療法の高額な費用
  • 機会
    • ジスキネジア調査と治療のための病院と大学の医療システム間の重要なパートナーシップ
    • 神経薬理学と外科的治療の選択肢の進歩により、症状を管理するための新たな道が開かれている
  • 課題
    • ジスキネジア治療に伴う副作用と合併症の管理
• 市場セグメンテーション分析
  • 治療タイプ：ジスキネジア運動の根底にある生化学的経路を標的とした薬理学的治療の必要性が高まっている
  • 患者ケア環境：病院全体で展開されている多次元戦略は、患者の多様なニーズを満たすためにケアソリューションをカスタマイズすることの重要性を強調している
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 ジスキネジア市場：治療タイプ別

• イントロダクション
• 非薬理学的アプローチ
  • 行動療法
  • 理学療法とリハビリテーション
• 薬剤療法
  • 抗コリン薬
  • ドーパミンモジュレーター
  • GABA作動薬
  • NMDA受容体拮抗薬
  • VMAT2阻害剤
• 外科的治療
  • アブレーション手術
  • 脳深部刺激療法（DBS）

第7章 ジスキネジア市場：ジスキネジアタイプ別

• イントロダクション
• アテトーゼ
• 舞踏病
• ジストニア関連ジスキネジア
• ミオクローヌスジスキネジア
• パーキンソン病ジスキネジア
• 痙性斜頸
• 遅刻ジスキネジア

第8章 ジスキネジア市場：投与経路別

• イントロダクション
• 静脈内（IV）と点滴ベース
• 経口
• 皮下
• 経皮

第9章 ジスキネジア市場：原因別

• イントロダクション
• 薬剤誘発性ジスキネジア
• 遺伝的ジスキネジア
• 特発性ジスキネジア
• 代謝ジスキネジア
• 神経変性疾患関連ジスキネジア

第10章 ジスキネジア市場：患者ケア環境別

• イントロダクション
• 在宅医療
• 病院
• 研究機関
• 専門クリニックとリハビリテーションセンター

第11章 南北アメリカのジスキネジア市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋のジスキネジア市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカのジスキネジア市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析、2024年
• FPNVポジショニングマトリックス、2024年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Addex therapeutics
• Amneal Pharmaceuticals, Inc.
• AstraZeneca
• Bayer Corporation
• Contera Pharma A/S
• F. Hoffmann-La Roche Ltd
• Lundbeck A/S
• Lupin Limited
• Luye Pharma Group
• Medtronic plc
• Mitsubishi Tanabe Pharma Corporation
• Neurocrine Biosciences, Inc.
• Novartis AG
• Pfizer Inc.
• SOM BIOTECH
• Sun Pharmaceutical Industries Ltd
• Supernus Pharmaceuticals, Inc.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd
• Voyager Therapeutics, Inc.
• Zydus Group

LIST OF FIGURES

• FIGURE 1. DYSKINESIA MARKET MULTI-CURRENCY
• FIGURE 2. DYSKINESIA MARKET MULTI-LANGUAGE
• FIGURE 3. DYSKINESIA MARKET RESEARCH PROCESS
• FIGURE 4. DYSKINESIA MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL DYSKINESIA MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL DYSKINESIA MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL DYSKINESIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL DYSKINESIA MARKET SIZE, BY CAUSE, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL DYSKINESIA MARKET SIZE, BY CAUSE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2024 VS 2030 (%)
• FIGURE 17. GLOBAL DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. AMERICAS DYSKINESIA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 19. AMERICAS DYSKINESIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. UNITED STATES DYSKINESIA MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 21. UNITED STATES DYSKINESIA MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 23. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 26. DYSKINESIA MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 27. DYSKINESIA MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. DYSKINESIA MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL DYSKINESIA MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL DYSKINESIA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. DYSKINESIA MARKET DYNAMICS
• TABLE 7. GLOBAL DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL DYSKINESIA MARKET SIZE, BY BEHAVIORAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL DYSKINESIA MARKET SIZE, BY PHYSICAL THERAPY & REHABILITATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL DYSKINESIA MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL DYSKINESIA MARKET SIZE, BY DOPAMINE MODULATORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL DYSKINESIA MARKET SIZE, BY GABA AGONISTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL DYSKINESIA MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL DYSKINESIA MARKET SIZE, BY VMAT2 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL DYSKINESIA MARKET SIZE, BY ABLATIVE SURGERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL DYSKINESIA MARKET SIZE, BY DEEP BRAIN STIMULATION (DBS), BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL DYSKINESIA MARKET SIZE, BY ATHETOSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL DYSKINESIA MARKET SIZE, BY CHOREA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL DYSKINESIA MARKET SIZE, BY DYSTONIA-RELATED DYSKINESIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL DYSKINESIA MARKET SIZE, BY MYOCLONIC DYSKINESIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL DYSKINESIA MARKET SIZE, BY PARKINSON'S DYSKINESIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL DYSKINESIA MARKET SIZE, BY SPASMODIC TORTICOLLIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL DYSKINESIA MARKET SIZE, BY TARDIVE DYSKINESIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL DYSKINESIA MARKET SIZE, BY INTRAVENOUS (IV) & INFUSION-BASED, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL DYSKINESIA MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL DYSKINESIA MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL DYSKINESIA MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL DYSKINESIA MARKET SIZE, BY DRUG-INDUCED DYSKINESIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL DYSKINESIA MARKET SIZE, BY GENETIC DYSKINESIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL DYSKINESIA MARKET SIZE, BY IDIOPATHIC DYSKINESIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL DYSKINESIA MARKET SIZE, BY METABOLIC DYSKINESIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL DYSKINESIA MARKET SIZE, BY NEURODEGENERATIVE DISORDER-ASSOCIATED DYSKINESIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL DYSKINESIA MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL DYSKINESIA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 45. GLOBAL DYSKINESIA MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 46. GLOBAL DYSKINESIA MARKET SIZE, BY SPECIALTY CLINICS & REHABILITATION CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 47. AMERICAS DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 48. AMERICAS DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
• TABLE 49. AMERICAS DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 50. AMERICAS DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 51. AMERICAS DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
• TABLE 52. AMERICAS DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 53. AMERICAS DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 54. AMERICAS DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 55. AMERICAS DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 56. ARGENTINA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 57. ARGENTINA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
• TABLE 58. ARGENTINA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 59. ARGENTINA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 60. ARGENTINA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
• TABLE 61. ARGENTINA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 62. ARGENTINA DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 63. ARGENTINA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 64. BRAZIL DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 65. BRAZIL DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
• TABLE 66. BRAZIL DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 67. BRAZIL DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 68. BRAZIL DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
• TABLE 69. BRAZIL DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 70. BRAZIL DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 71. BRAZIL DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 72. CANADA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 73. CANADA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
• TABLE 74. CANADA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 75. CANADA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 76. CANADA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
• TABLE 77. CANADA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 78. CANADA DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 79. CANADA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 80. MEXICO DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 81. MEXICO DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
• TABLE 82. MEXICO DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 83. MEXICO DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 84. MEXICO DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
• TABLE 85. MEXICO DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 86. MEXICO DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 87. MEXICO DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 88. UNITED STATES DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 89. UNITED STATES DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
• TABLE 90. UNITED STATES DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 91. UNITED STATES DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 92. UNITED STATES DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
• TABLE 93. UNITED STATES DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 94. UNITED STATES DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 95. UNITED STATES DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 96. UNITED STATES DYSKINESIA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 97. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 98. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
• TABLE 99. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 100. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 101. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
• TABLE 102. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 103. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 104. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 105. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 106. AUSTRALIA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 107. AUSTRALIA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
• TABLE 108. AUSTRALIA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 109. AUSTRALIA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 110. AUSTRALIA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
• TABLE 111. AUSTRALIA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 112. AUSTRALIA DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 113. AUSTRALIA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 114. CHINA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 115. CHINA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
• TABLE 116. CHINA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 117. CHINA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 118. CHINA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
• TABLE 119. CHINA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 120. CHINA DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 121. CHINA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 122. INDIA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 123. INDIA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
• TABLE 124. INDIA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 125. INDIA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 126. INDIA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
• TABLE 127. INDIA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 128. INDIA DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 129. INDIA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 130. INDONESIA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 131. INDONESIA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
• TABLE 132. INDONESIA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 133. INDONESIA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 134. INDONESIA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
• TABLE 135. INDONESIA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 136. INDONESIA DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 137. INDONESIA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 138. JAPAN DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 139. JAPAN DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
• TABLE 140. JAPAN DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 141. JAPAN DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 142. JAPAN DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
• TABLE 143. JAPAN DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 144. JAPAN DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 145. JAPAN DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 146. MALAYSIA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 147. MALAYSIA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
• TABLE 148. MALAYSIA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 149. MALAYSIA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 150. MALAYSIA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
• TABLE 151. MALAYSIA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 152. MALAYSIA DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 153. MALAYSIA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 154. PHILIPPINES DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 155. PHILIPPINES DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
• TABLE 156. PHILIPPINES DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 157. PHILIPPINES DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 158. PHILIPPINES DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
• TABLE 159. PHILIPPINES DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 160. PHILIPPINES DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 161. PHILIPPINES DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 162. SINGAPORE DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 163. SINGAPORE DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
• TABLE 164. SINGAPORE DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 165. SINGAPORE DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 166. SINGAPORE DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
• TABLE 167. SINGAPORE DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 168. SINGAPORE DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 169. SINGAPORE DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 170. SOUTH KOREA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 171. SOUTH KOREA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
• TABLE 172. SOUTH KOREA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 173. SOUTH KOREA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 174. SOUTH KOREA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
• TABLE 175. SOUTH KOREA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 176. SOUTH KOREA DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 177. SOUTH KOREA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 178. TAIWAN DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 179. TAIWAN DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
• TABLE 180. TAIWAN DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 181. TAIWAN DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 182. TAIWAN DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
• TABLE 183. TAIWAN DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 184. TAIWAN DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 185. TAIWAN DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 186. THAILAND DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 187. THAILAND DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
• TABLE 188. THAILAND DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 189. THAILAND DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 190. THAILAND DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
• TABLE 191. THAILAND DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 192. THAILAND DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 193. THAILAND DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 194. VIETNAM DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 195. VIETNAM DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
• TABLE 196. VIETNAM DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 197. VIETNAM DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 198. VIETNAM DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
• TABLE 199. VIETNAM DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 200. VIETNAM DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 201. VIETNAM DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 202. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 203. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
• TABLE 204. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 205. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 206. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
• TABLE 207. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 208. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 209. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 210. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 211. DENMARK DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 212. DENMARK DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
• TABLE 213. DENMARK DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 214. DENMARK DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 215. DENMARK DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
• TABLE 216. DENMARK DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 217. DENMARK DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 218. DENMARK DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 219. EGYPT DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 220. EGYPT DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
• TABLE 221. EGYPT DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 222. EGYPT DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 223. EGYPT DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
• TABLE 224. EGYPT DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 225. EGYPT DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 226. EGYPT DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 227. FINLAND DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 228. FINLAND DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
• TABLE 229. FINLAND DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 230. FINLAND DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 231. FINLAND DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
• TABLE 232. FINLAND DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 233. FINLAND DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 234. FINLAND DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 235. FRANCE DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 236. FRANCE DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
• TABLE 237. FRANCE DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 238. FRANCE DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 239. FRANCE DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
• TABLE 240. FRANCE DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 241. FRANCE DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 242. FRANCE DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 243. GERMANY DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 244. GERMANY DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
• TABLE 245. GERMANY DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 246. GERMANY DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 247. GERMANY DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
• TABLE 248. GERMANY DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 249. GERMANY DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 250. GERMANY DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 251. ISRAEL DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 252. ISRAEL DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
• TABLE 253. ISRAEL DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 254. ISRAEL DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 255. ISRAEL DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
• TABLE 256. ISRAEL DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 257. ISRAEL DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 258. ISRAEL DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 259. ITALY DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 260. ITALY DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
• TABLE 261. ITALY DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 262. ITALY DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 263. ITALY DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
• TABLE 264. ITALY DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 265. ITALY DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 266. ITALY DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 267. NETHERLANDS DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 268. NETHERLANDS DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
• TABLE 269. NETHERLANDS DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 270. NETHERLANDS DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 271. NETHERLANDS DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
• TABLE 272. NETHERLANDS DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 273. NETHERLANDS DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 274. NETHERLANDS DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 275. NIGERIA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 276. NIGERIA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
• TABLE 277. NIGERIA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 278. NIGERIA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 279. NIGERIA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
• TABLE 280. NIGERIA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 281. NIGERIA DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 282. NIGERIA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 283. NORWAY DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 284. NORWAY DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
• TABLE 285. NORWAY DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 286. NORWAY DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 287. NORWAY DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
• TABLE 288. NORWAY DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 289. NORWAY DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 290. NORWAY DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 291. POLAND DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 292. POLAND DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
• TABLE 293. POLAND DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 294. POLAND DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 295. POLAND DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
• TABLE 296. POLAND DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 297. POLAND DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 298. POLAND DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 299. QATAR DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 300. QATAR DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
• TABLE 301. QATAR DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 302. QATAR DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 303. QATAR DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
• TABLE 304. QATAR DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 305. QATAR DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 306. QATAR DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 307. RUSSIA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 308. RUSSIA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
• TABLE 309. RUSSIA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 310. RUSSIA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 311. RUSSIA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
• TABLE 312. RUSSIA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 313. RUSSIA DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 314. RUSSIA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 315. SAUDI ARABIA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 316. SAUDI ARABIA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
• TABLE 317. SAUDI ARABIA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 318. SAUDI ARABIA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 319. SAUDI ARABIA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
• TABLE 320. SAUDI ARABIA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 321. SAUDI ARABIA DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 322. SAUDI ARABIA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 323. SOUTH AFRICA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 324. SOUTH AFRICA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
• TABLE 325. SOUTH AFRICA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 326. SOUTH AFRICA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 327. SOUTH AFRICA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
• TABLE 328. SOUTH AFRICA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 329. SOUTH AFRICA DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 330. SOUTH AFRICA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 331. SPAIN DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 332. SPAIN DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
• TABLE 333. SPAIN DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 334. SPAIN DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 335. SPAIN DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
• TABLE 336. SPAIN DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 337. SPAIN DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 338. SPAIN DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 339. SWEDEN DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 340. SWEDEN DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
• TABLE 341. SWEDEN DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 342. SWEDEN DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 343. SWEDEN DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
• TABLE 344. SWEDEN DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 345. SWEDEN DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 346. SWEDEN DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 347. SWITZERLAND DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 348. SWITZERLAND DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2030 (USD MILLION)
• TABLE 349. SWITZERLAND DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 350. SWITZERLAND DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 351. SWITZERLAND DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2030 (USD MILLION)
• TABLE 352. SWITZERLAND DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 353. SWITZERLAND DYSKINESIA MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
• TABLE 354. SWITZERLAND DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 355. TURKEY DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 356. TUR

The Dyskinesia Market was valued at USD 2.42 billion in 2024 and is projected to grow to USD 2.59 billion in 2025, with a CAGR of 7.30%, reaching USD 3.70 billion by 2030.

In the evolving landscape of healthcare, the condition of dyskinesia remains a critical area of study and attention. This report offers an in-depth look at the dyskinesia market, providing clarity on its current state as well as future possibilities. The discussion begins with a focused analysis of the clinical nature of dyskinesia, a movement disorder characterized by involuntary muscle movements that affect patient quality of life. As medical professionals and decision-makers seek to address the challenges posed by this condition, the report delves into a blend of empirical research and strategic market analysis. The narrative examines historical trends, diagnostic complexities, and the pressing need for comprehensive treatment options. Through clear and direct analysis, the report lays the foundation for understanding the multifaceted market dynamics and the roles of various stakeholders. Rich insights drawn from vast clinical data and emerging treatment paradigms underscore the criticality of timely medical interventions and holistic patient care. This introductory segment establishes the background that frames the subsequent sections, encouraging readers to explore the transformative changes and granular segmentation insights that offer an informed perspective on market evolution.

Transformative Shifts in the Dyskinesia Market Landscape

Over recent years, the dyskinesia market has experienced a series of transformative shifts driven by rapid advancements in both technology and medical research. The landscape has been reshaped by the integration of innovative treatment protocols alongside improved diagnostic techniques, enabling more personalized and effective therapeutic strategies. Clinical breakthroughs, alongside comprehensive data analytics, have propelled the market into a phase where precision medicine is becoming central to treatment regimens. Traditional methodologies are giving way to evidence-based, patient-centric approaches that not only address the symptoms but also target the underlying causes and nuances of dyskinesia. In this new paradigm, stakeholders are embracing digital solutions, telemedicine, and enhanced monitoring systems that together contribute to more agile and adaptive treatment frameworks. With evolving regulatory standards and creative clinical trial designs, there is an increased emphasis on gathering real-world evidence on emerging therapies. This continuous transformation not only deepens the understanding of dyskinesia but also stimulates the development of novel interventions, ensuring that the market remains dynamic and responsive to the complex needs of patients.

Detailed Segmentation Insights for a Nuanced Market View

The market is dissected through extensive segmentation that provides a granular insight into treatment strategies and patient interactions. When considering treatment type, the market is examined across non-pharmacological approaches, pharmacological treatments, and surgical interventions. The non-pharmacological category is further nuanced by exploring behavioral therapy and physical therapy along with rehabilitation protocols, while pharmacological treatments are meticulously classified into groups that include anticholinergics, dopamine modulators, GABA agonists, NMDA receptor antagonists, and VMAT2 inhibitors. Surgical treatments are analyzed by evaluating both ablative surgery and the increasingly significant deep brain stimulation procedures. Further segmentation based on dyskinesia type allows for the categorization of conditions such as athetosis, chorea, dystonia-related dyskinesia, myoclonic dyskinesia, Parkinson's dyskinesia, spasmodic torticollis, and tardive dyskinesia. The route of administration offers another layer of sophistication by differentiating between intravenous and infusion-based methods, oral forms, subcutaneous delivery, and transdermal systems. Moreover, understanding the underlying causes-ranging from drug-induced, genetic, idiopathic, and metabolic dyskinesia to neurodegenerative disorder-associated dyskinesia-provides a comprehensive framework. Finally, the market is further segmented based on patient care settings, encompassing home care, hospitals, research institutes, and specialty clinics along with rehabilitation centers. This multidimensional segmentation highlights the complexity and tailored approaches necessary for addressing the diverse needs of the dyskinesia patient population.

Based on Treatment Type, market is studied across Non-Pharmacological Approaches, Pharmacological Treatments, and Surgical Treatments. The Non-Pharmacological Approaches is further studied across Behavioral Therapy and Physical Therapy & Rehabilitation. The Pharmacological Treatments is further studied across Anticholinergics, Dopamine Modulators, GABA Agonists, NMDA Receptor Antagonists, and VMAT2 Inhibitors. The Surgical Treatments is further studied across Ablative Surgery and Deep Brain Stimulation (DBS).

Based on Dyskinesia Type, market is studied across Athetosis, Chorea, Dystonia-Related Dyskinesia, Myoclonic Dyskinesia, Parkinson's Dyskinesia, Spasmodic Torticollis, and Tardive Dyskinesia.

Based on Route of Administration, market is studied across Intravenous (IV) & Infusion-Based, Oral, Subcutaneous, and Transdermal.

Based on Cause, market is studied across Drug-Induced Dyskinesia, Genetic Dyskinesia, Idiopathic Dyskinesia, Metabolic Dyskinesia, and Neurodegenerative Disorder-Associated Dyskinesia.

Based on Patient Care Settings, market is studied across Home Care, Hospitals, Research Institutes, and Specialty Clinics & Rehabilitation Centers.

Global Regional Insights Shaping Market Dynamics

Market performance and growth are highly influenced by regional variations that depict distinct healthcare approaches and regulatory environments. Analysis indicates that the Americas are witnessing a robust integration of advanced therapeutic practices combined with supportive health policies, which further drive market expansions. In regions classified under Europe, Middle East & Africa, there is an evident blend of established medical systems and emerging innovation, where strategic investments in research and clinical infrastructure are gradually transforming patient care delivery. The Asia-Pacific region, on the other hand, presents a dynamic landscape that is marked by rapid urbanization, increasing healthcare awareness, and substantial infrastructure modernization. These regions, together with their unique regulatory frameworks and investment climates, create a mosaic of opportunities and challenges that require adaptive strategies from both market entrants and longstanding industry players. The region-specific insights help in identifying where the market resilience is strongest, and where targeted efforts could yield expedient results, underpinning the strategic decisions made by industry stakeholders.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Insightful Key Companies Driving Innovation

A close examination of the corporate domain reveals a competitive ecosystem characterized by both established multinationals and agile innovators. Industry leaders such as AbbVie Inc. and AstraZeneca have charted significant progress through their research initiatives, while organizations like Addex therapeutics and Amneal Pharmaceuticals, Inc. bring forward innovative perspectives that challenge traditional methodologies. Bayer Corporation, Contera Pharma A/S, and F. Hoffmann-La Roche Ltd are pivotal in driving breakthrough solutions that redefine treatment paradigms. Companies such as Lundbeck A/S and Lupin Limited complement these efforts with robust research frameworks and clinical expertise, strengthening the overall market fabric. Additionally, entities like Luye Pharma Group, Medtronic plc, and Mitsubishi Tanabe Pharma Corporation have carved out distinguished niches within surgical and non-surgical intervention spheres. Leaders including Neurocrine Biosciences, Inc., Novartis AG, and Pfizer Inc. continue to shape market dynamics with their diversified portfolios, while SOM BIOTECH, Sun Pharmaceutical Industries Ltd, and Supernus Pharmaceuticals, Inc. contribute actively to product innovation. Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd, Voyager Therapeutics, Inc., and Zydus Group also emerge as key players who are continuously pushing the boundaries of research, ensuring a competitive yet dynamic marketplace that fosters collaboration and sustainable growth.

The report delves into recent significant developments in the Dyskinesia Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Addex therapeutics, Amneal Pharmaceuticals, Inc., AstraZeneca, Bayer Corporation, Contera Pharma A/S, F. Hoffmann-La Roche Ltd, Lundbeck A/S, Lupin Limited, Luye Pharma Group, Medtronic plc, Mitsubishi Tanabe Pharma Corporation, Neurocrine Biosciences, Inc., Novartis AG, Pfizer Inc., SOM BIOTECH, Sun Pharmaceutical Industries Ltd, Supernus Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd, Voyager Therapeutics, Inc., and Zydus Group. Actionable Recommendations for Driving Industry Growth

For industry leaders striving to optimize their strategies in the dyskinesia market, several actionable recommendations emerge from this comprehensive analysis. First, it is essential to invest in integrated research and clinical trials that foster collaboration across multiple treatment categories. Focusing on the convergence of non-pharmacological, pharmacological, and surgical techniques can lead to optimized, patient-specific intervention pathways. Companies should leverage emerging technologies and data analytics to gain deeper insights into treatment efficacy and patient outcomes, thereby enabling more informed decision-making. Next, the importance of diversifying portfolio strategies cannot be overstated; incorporating a mix of traditional treatments along with innovative approaches such as deep brain stimulation can significantly enhance competitive positioning. Embracing a global strategy that takes into account regional nuances will be critical for market expansion. Collaborative partnerships with research institutes and clinical organizations can support accelerated innovation. Proactive engagement with regulatory bodies to streamline approval processes and facilitate market entry is also vital. Ultimately, industry leaders need to continuously re-evaluate and refine their strategic frameworks, ensuring that investments in research, development, and technology remain at the forefront of addressing the intricate challenges posed by dyskinesia.

Concluding Analysis of the Dyskinesia Market Trends

In summary, the dyskinesia market is undergoing significant transformation, marked by rapid innovation, comprehensive segmentation, and diverse regional trends. With an in-depth focus on technological advancements, clinical breakthroughs, and tailored treatment strategies, stakeholders are well-equipped to navigate the complexities of this evolving landscape. The expansive segmentation framework provides a nuanced understanding of treatment modalities, dyskinesia subtypes, routes of administration, underlying causes, and patient care settings, all of which culminate in a precise mapping of market opportunities and challenges. Regional insights reveal distinct growth patterns influenced by healthcare infrastructure and investment environments, while the competitive analysis underscores the pivotal role played by leading companies. Through a balanced approach that combines scientific research with strategic market positioning, this report offers a timely reflection on the dynamic trends that define the current market environment. The analysis not only provides a robust foundation for future technological and clinical advancements but also charts a course for sustainable growth, reaffirming the industry's commitment to enhancing patient outcomes and overall healthcare delivery.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of Parkinson's disease and other neurological disorders
    • 5.1.1.2. Supportive regulatory policies and expedited drug approval processes fostering market growth for dyskinesia treatments
    • 5.1.1.3. Increasing awareness among healthcare professionals and patients about dyskinesia and its management
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of treatment and therapies for dyskinesia management
  • 5.1.3. Opportunities
    • 5.1.3.1. Significant partnerships between hospital and a university health system for Dyskinesia research and treatment
    • 5.1.3.2. Advancements in neuropharmacology and surgical treatment options that are providing new avenues for managing dyskinesia symptoms
  • 5.1.4. Challenges
    • 5.1.4.1. Managing side effects and complications associated with dyskinesia treatments
• 5.2. Market Segmentation Analysis
  • 5.2.1. Treatment Type: Increasing need for pharmacological treatments targeting the biochemical pathways underlying dyskinetic movements.
  • 5.2.2. Patient Care Settings: Multi-dimensional strategies deployed across hospitals underscore the importance of customizing care solutions to meet the diverse needs of dyskinesia patients
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Dyskinesia Market, by Treatment Type

• 6.1. Introduction
• 6.2. Non-Pharmacological Approaches
  • 6.2.1. Behavioral Therapy
  • 6.2.2. Physical Therapy & Rehabilitation
• 6.3. Pharmacological Treatments
  • 6.3.1. Anticholinergics
  • 6.3.2. Dopamine Modulators
  • 6.3.3. GABA Agonists
  • 6.3.4. NMDA Receptor Antagonists
  • 6.3.5. VMAT2 Inhibitors
• 6.4. Surgical Treatments
  • 6.4.1. Ablative Surgery
  • 6.4.2. Deep Brain Stimulation (DBS)

7. Dyskinesia Market, by Dyskinesia Type

• 7.1. Introduction
• 7.2. Athetosis
• 7.3. Chorea
• 7.4. Dystonia-Related Dyskinesia
• 7.5. Myoclonic Dyskinesia
• 7.6. Parkinson's Dyskinesia
• 7.7. Spasmodic Torticollis
• 7.8. Tardive Dyskinesia

8. Dyskinesia Market, by Route of Administration

• 8.1. Introduction
• 8.2. Intravenous (IV) & Infusion-Based
• 8.3. Oral
• 8.4. Subcutaneous
• 8.5. Transdermal

9. Dyskinesia Market, by Cause

• 9.1. Introduction
• 9.2. Drug-Induced Dyskinesia
• 9.3. Genetic Dyskinesia
• 9.4. Idiopathic Dyskinesia
• 9.5. Metabolic Dyskinesia
• 9.6. Neurodegenerative Disorder-Associated Dyskinesia

10. Dyskinesia Market, by Patient Care Settings

• 10.1. Introduction
• 10.2. Home Care
• 10.3. Hospitals
• 10.4. Research Institutes
• 10.5. Specialty Clinics & Rehabilitation Centers

11. Americas Dyskinesia Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Dyskinesia Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Dyskinesia Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2024
• 14.2. FPNV Positioning Matrix, 2024
• 14.3. Competitive Scenario Analysis
  • 14.3.1. PCD Research and NATA co-fund grant to advance therapy for primary ciliary dyskinesia
  • 14.3.2. Teva neuroscience secures FDA approval of once-daily Austedo XR for enhanced management of tardive dyskinesia and Huntington chorea
  • 14.3.3. Connecticut Children's and UConn Health partner to launch state's only primary ciliary dyskinesia center
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Addex therapeutics
• 3. Amneal Pharmaceuticals, Inc.
• 4. AstraZeneca
• 5. Bayer Corporation
• 6. Contera Pharma A/S
• 7. F. Hoffmann-La Roche Ltd
• 8. Lundbeck A/S
• 9. Lupin Limited
• 10. Luye Pharma Group
• 11. Medtronic plc
• 12. Mitsubishi Tanabe Pharma Corporation
• 13. Neurocrine Biosciences, Inc.
• 14. Novartis AG
• 15. Pfizer Inc.
• 16. SOM BIOTECH
• 17. Sun Pharmaceutical Industries Ltd
• 18. Supernus Pharmaceuticals, Inc.
• 19. Takeda Pharmaceutical Company Limited
• 20. Teva Pharmaceutical Industries Ltd
• 21. Voyager Therapeutics, Inc.
• 22. Zydus Group